Drugs / JNJ-90009530
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05784441 | Nov 2023 → Jan 2027 expected | B-cell non-Hodgkin lymphoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-90009530 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05784441 ↗ |
| Modality | Cell therapy | “Chimeric Antigen Receptor (CAR) - T therapy” NCT05784441 ↗ |